inspirator schreef op 27 april 2017 18:08:
Goed zaken doen met partijen met een dikke beurs
Changing lanes to the agreement with MDxHealth, the two parties will enter a collaboration in the fields of epigenetics and molecular diagnostics. The agreement builds on a long-standing relationship spanning more than a decade, but the new agreement will allow MDxHealth and EXAS to share proprietary technologies arising from their respective ground-breaking discovery and development efforts in the fields of epigenetics and molecular diagnostics. During the course of the collaboration, the parties may identify opportunities to share technologies in a range of indications, including urologic and lung cancers.
At the same time, with the execution of the collaboration agreement, EXAS is also acquiring MDxHealth patents directed toward colorectal cancer, including its DNA methylation biomarker, NDRG4, as well as technology covering the use of FIT (fecal immunochemical test) in combination with methylation. These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.
Gaat Exact Sciences AssureMdx vertegenwoordigen voor MdxHealth